Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion
Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion PR Newswire
Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion PR Newswire
Why the right prostate cancer treatment isn't the same for everyone PhillyVoice
MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going TradingView
A lung cancer treatment showed 90.5% disease control in an interim trial assessment stocktitan.net
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer GlobeNewswire
E. coli in uncooked meat can cause diarrhea and food poisoning. Scientists, however, have found a way to turn the bacterium into a delivery agent that takes drugs straight to a tumor and transforms it into a tiny cancer drug dispensary.
City of Hope develops adaptive plug-and-play CAR T technology to attack tumors News-Medical
У акций Grail был лучший день за 1,5 года. Регулятор может одобрить ее тест на рак TradingView
Ученые нашли способ «выжигать» опухоль магнитным полем: в «Сириусе» создали необычную жидкость для борьбы с раком Izhlife.ru
У акций Grail был лучший день за 1,5 года. Регулятор может одобрить ее тест на рак Oninvest
A head-and-neck cancer trial reported 39.3 months of median survival Stock Titan
What drives time-to-randomization in oncology trials? Pharmaceutical Technology